Lenalidomide Based Immunotherapy in the Treatment of FL
Lenalidomide Based Immunotherapy efficacy related molecular biomarker in follicular lymphoma
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
115
Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0
Ruijin Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGCR
Complete response rate
Time frame: 12 weeks
PFS
Progression free survival rate
Time frame: 1 year
OS
Overall survival rate
Time frame: 1 year
ORR
Overall response rate
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.